![Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy | HCV Guidance Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy | HCV Guidance](https://www.hcvguidelines.org/sites/default/files/default_images/Figure%201%20Recommended%20Management%20of%20DAA%20Treatment%20Interuptions.png)
Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy | HCV Guidance
![Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits - The Lancet Regional Health – Western Pacific Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits - The Lancet Regional Health – Western Pacific](https://www.thelancet.com/cms/attachment/8840effc-b509-4165-ae7e-c5e08090b170/gr1_lrg.jpg)
Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits - The Lancet Regional Health – Western Pacific
![aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis - ScienceDirect aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168827820304785-fx1.jpg)
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis - ScienceDirect
![Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population | Epidemiology & Infection | Cambridge Core Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population | Epidemiology & Infection | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20180307062252846-0234:S0950268818000080:S0950268818000080_tab3.gif?pub-status=live)